[177Lu]Lu-PSMA-617 significantly improves radiographic progression-free survival and overall quality of life for patients with taxane-naive mCRPC, while minimizing adverse events. The study's findings suggest that [177Lu]Lu-PSMA-617 may change the treatment paradigm for pre-taxane advanced prostate cancer patients.
Dr. George Sgouros has been recognized for his outstanding contributions to the field of nuclear medicine, with a focus on calculating precise radiation dosages for cancer patients. His research aims to maximize treatment benefits and minimize side effects through targeted alpha-emitter therapy.
Carolyn J. Anderson has made significant contributions to the development of radiometal-based agents for diagnostic imaging and targeted radionuclide therapy of cancer, a field known as 'theranostics.' Her work led to the FDA approval of Lu-177 DOTATATE for treating neuroendocrine tumors.
A multi-center study found that healthy older adults with beta-amyloid deposits showed significantly less training improvement in cognitive tasks. However, individuals without amyloid deposits demonstrated better cognitive plasticity and training effectiveness.
A novel imaging approach, Ga-DOTATATE PET/CT, offers enhanced sensitivity and specificity for detecting residual/recurrent tumors in patients with head and neck paragangliomas. This method improves the differentiation between tumor and scar tissue post-surgery.
Cybil Nielsen has been elected as the 2024-25 president-elect of the Society of Nuclear Medicine and Molecular Imaging Technologist Section. She aims to expand educational programs, mentorship opportunities, and networking events to facilitate continuous learning and career advancement among members.
Julie Dawn Bolin, a seasoned nuclear medicine technologist and educator, has been elected as the new president of the SNMMI Technologist Section for 2024-25. Bolin aims to advance the field by bolstering educational initiatives, championing advocacy efforts, and promoting access to education and healthcare in marginalized communities.
A new study has found that FAPI PET/CT is more effective than FDG in predicting progressive pulmonary fibrosis in ILD patients. The study's results suggest that FAPI PET/CT can identify high-risk patients who require closer monitoring or preventive treatment.
Researchers found that FAP-targeted radioligand therapy controlled disease progression in nearly half of patients with advanced sarcoma, and was well-tolerated without critical organ radiation dose levels being reached. The study's results indicate a promising approach for this patient group with limited treatment options.
Researchers developed a novel radiotracer to detect Claudin18.2 in gastrointestinal cancers, allowing for early diagnosis and targeted therapy optimization. The radiotracer enables whole-body PET imaging within one day, increasing compliance and reducing radiation exposure.
The SNMMI Annual Meeting will showcase new radiopharmaceuticals, instrumentation, and techniques for managing various diseases. Over 6,500 attendees from around the globe will participate in more than 100 scientific and CE sessions.
A new PET imaging biomarker, Gal-1, has been identified to predict the tumor responses before starting immune checkpoint blockade therapy. This enables targeted interventions and improves patient outcomes by facilitating patient stratification and optimizing immunotherapy.
A new supplement to The Journal of Nuclear Medicine highlights China's significant advances in research and development, including long-field PET scanners and innovative theranostic concepts. The supplement aims to inform international collaborations and multicenter studies, featuring top experts in molecular imaging and theranostics.
A novel investigational PET imaging agent, <sup> 68 </sup> Ga-DPI-4452 (Debio 0328), has been shown to provide rapid and accurate visualization of lesions in clear cell renal cell cancer patients. The agent offers a superior alternative to standard CT imaging and could potentially be used as part of a theranostic pair.
A novel SPECT/CT acquisition method utilizing lead-212 (212Pb) can accurately detect radiopharmaceutical biodistribution in a convenient manner. This technique has the potential to change practice and increase access for patients around the world by providing more precise treatment options.
A new study found that PET/MRI can accurately classify prostate cancer patients and help avoid unnecessary biopsies. The PRIMARY scoring system showed that over 80% of unnecessary biopsies could be avoided while missing only 12.5% of clinically significant prostate cancer cases.
Researchers developed a novel theranostic platform that combines PET imaging and therapeutic radionuclides to detect and treat ovarian cancer. The system uses the huAR9.6 antibody to target the MUC16 protein, showing promise for improved patient survival rates.
Researchers have developed a new method to trigger and image seizures in epilepsy patients, allowing for real-time data collection to tailor epilepsy surgery. This method is clinically feasible, convenient, and spares resources, providing valuable information for successful surgeries.
Researchers developed a novel PET tracer that can map fructose metabolism, differentiating diseased tissues from healthy ones. This non-invasive technique has the potential to detect diseases such as stroke, brain metastases, and heart attacks more sensitively.
New research reveals that radioguided surgery can effectively detect and remove metastatic pelvic lymph nodes in newly diagnosed prostate cancer patients. The procedure targets the prostate-specific membrane antigen, improving nodal staging to guide treatment recommendations.
Recent advances in permeating the brain-blood barrier hold promise for using radiopharmaceuticals to treat brain tumors. Theranostic approaches show encouraging preliminary results, particularly for meningiomas and pediatric brain tumors.
A retrospective study found that PRRT was effective in controlling hypoglycemia in 81% of patients with malignant insulinomas, enabling 58% to reduce medication use. The treatment resulted in improved symptom control and reduced potential drug side effects for over 80% of patients.
A novel PET imaging technique can detect active inflammation in the body before clinical symptoms arise, using a PET tracer that binds to proteins present on activated immune cells. This makes it easier for physicians to correctly diagnose and treat patients with rheumatoid arthritis.
A novel imaging approach has been shown to accurately identify sub-types of primary aldosteronism, an adrenal gland disorder. The technique provides a clearer picture of the adrenal glands, helping doctors decide whether surgery is necessary.
A novel PET imaging agent has been found to effectively identify medullary thyroid cancer (MTC) in preclinical and clinical studies. The compound demonstrates favorable tumor uptake and improved activity clearance from off-target tissues, potentially enhancing lesion detection and enabling targeted MTC radioligand therapy.
The Society of Nuclear Medicine and Molecular Imaging has published a new procedure standard/practice guideline for estrogen receptor imaging of breast cancer patients using FES PET. The guideline aims to promote the appropriate use of FES PET and enhance research, providing advantages in assessing tumor ER expression and predicting re...
A new PET imaging tracer has been developed to detect a common cancer gene mutation with high accuracy. The tracer targets the KRAS G12C protein, allowing for early identification of patients who can benefit from targeted therapy.
A new study found that Ga-68 FAPI PET imaging can effectively detect and stage pancreatic cancer, outperforming existing methods. The imaging modality also showed potential for future targeted radiopharmaceutical therapies.
Researchers have developed a novel PET radiotracer that enables early detection of inflammatory bowel disease (IBD) with high spatial and molecular specificity. The imaging tool targets the IBD biomarker IL12/23p40, providing detailed information for accurate diagnosis and treatment.
A study found that bone scans overstage prostate cancer at initial staging, leading to potential withholding of definitive therapy from patients. PSMA PET is more accurate than CT and bone scans for staging patients with prostate cancer.
A new AI tool provides fully automated, easy-to-use evaluation of brain tumors using amino acid PET scans. The deep learning-based segmentation algorithm assesses treatment response with quality comparable to that of an experienced physician.
Researchers found a single dose of ADC therapy combined with lovastatin reduced tumor volume rates similar to multiple doses in preclinical settings. Immuno-PET scans also monitored HER2 tumor levels after treatment, offering real-time insights into therapy response and potential personalized cancer treatments.
A new tau PET radiotracer, 18F-SNFT-1, demonstrates high sensitivity and specificity in identifying Alzheimer's disease. This improved tracer enables earlier diagnosis and potential therapeutic interventions.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients. Whole-body PET/CT enables quantification of HER2 expression and predicts metabolic response, potentially sparing patients from unnecessary side effects.
A new nuclear medicine treatment has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting. The therapy targets the HER2 protein and achieved high potency while maintaining an acceptable safety profile.
The Society of Nuclear Medicine and Molecular Imaging has issued a new consensus statement to standardize the selection and management of patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with Lu-177 PSMA radionuclide therapy. The statement recommends performing PSMA PET within three months of treatment or sin...
A study found that PSMA PET/CT can accurately diagnose advanced prostate cancer in elderly patients without the need for a biopsy. The procedure reduced the number of biopsies and associated complications, while providing clinical suspicion-based staging data.
A novel PET perfusion radiotracer, 18F-flurpiridaz, demonstrates high diagnostic efficacy for obese patients with coronary artery disease, outperforming traditional imaging methods. The study showed improved sensitivity and specificity in diagnosing significant CAD, even at lower radiation doses.
A study using molecular imaging found that individuals with obesity respond differently to food cues than normal-weight individuals, with altered connectivity between brain networks. The research offers valuable insights into potential medical interventions for obesity, including novel drug treatments and behavioral therapies.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
Cathy Sue Cutler is elected SNMMI president-elect to tackle talent shortages, funding issues and education gaps in the field. She aims to attract talent, enhance training opportunities and educate practitioners on theranostics for personalized medicine.
SNMMI has elected Jean-Luc C. Urbain as Vice President-Elect, who will focus on bringing new precision oncology nuclear therapies to the clinic. He aims to implement SNMMI's strategic plan, promoting its brand globally and increasing membership and financial support.
A study found that monitoring early-response biomarkers enables personalized dosing in prostate cancer treatment, improving patient outcomes. The approach allowed patients to take
The Society of Nuclear Medicine and Molecular Imaging has recognized ten new SNMMI Fellows, including Virginia Pappas as an honorary Fellow, for their excellence in volunteer service and scientific discovery. The SNMMI Fellowship is among the most prestigious formal recognitions available to long-time members.
Researchers developed a computational technique combining genomic and tau PET imaging data to identify four subtypes of Alzheimer's disease. The integrated approach also revealed top genes associated with each subtype. This personalized diagnostic technique has potential for broad utility across various diseases.
Helen Nadel, MD, FRCPC, has been named SNMMI President, aiming to raise awareness of and access to nuclear medicine, molecular imaging, and theranostics. She will focus on precision health, standardization, diversity, and increasing qualified professionals in the field.
Dr. Peter J. H. Scott has made significant contributions to radiopharmaceutical sciences through his development of new methods and technologies. He has also received numerous awards for his research, including the Sam Gambhir Trailblazer Award.
Umar Mahmood, a prominent researcher and leader in the field of nuclear medicine and molecular imaging, has been awarded the first annual SNMMI Minoshima-Pappas Transformational Leadership Award. His work focuses on developing new imaging methods for disease process examination and early therapeutic response assessment.
Dmitry Beyder has been elected as the president of the SNMMI-TS for 2023-24, aiming to increase technologists' roles in providing theranostics and nuclear medicine therapy. He brings extensive experience from various positions in the field.
SNMMI-TS elects Julie Dawn Bolin as president-elect, focusing on educating students about nuclear medicine careers and improving professional development. Bolin brings extensive experience in nuclear medicine technology and education.